BeOne Medicines (BEIGF) Cash from Operations (QoQ) (2015 - 2026)
Powered by 
Analysis
BeOne Medicines (BEIGF) Cash from Operations (QoQ) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.53 Bn | 625.77 Bn | 17.26 Bn |
| 2 | AbbVie | 442.27 Bn | 435.70 Bn | 12.70 Bn |
| 3 | Merck | 366.81 Bn | 359.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn |
| 5 | Pfizer | 159.37 Bn | 147.67 Bn | 10.94 Bn |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.12 Bn | 44.12 Bn | - |
| 8 | Incyte | 25.49 Bn | 20.95 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.55 Bn | 18.89 Bn | 683.80 Mn |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 129.87% |
| Mar 31, 2026 | -51.76% |
| Dec 31, 2025 | 3.68% |
| Sep 30, 2025 | 52.71% |
| Jun 30, 2025 | 497.97% |
| Mar 31, 2025 | -41.35% |
| Dec 31, 2024 | -60.10% |
| Sep 30, 2024 | 297.06% |
| Jun 30, 2024 | 69.02% |
| Mar 31, 2024 | -39.22% |
| Dec 31, 2023 | -183.61% |
| Sep 30, 2023 | 73.41% |
| Jun 30, 2023 | 47.87% |
| Mar 31, 2023 | -77.18% |
| Dec 31, 2022 | 43.37% |
| Sep 30, 2022 | -47.89% |
| Jun 30, 2022 | -60.62% |
| Mar 31, 2022 | 53.42% |
| Dec 31, 2021 | -2.45% |
| Sep 30, 2021 | -17.95% |